Meta‐analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapy. BJS 2018; 105: 1098-1106.
Published: 4th July 2018
Authors: C. A. Fleming, H. M. Heneghan, D. O'Brien, D. P. McCartan, E. W. McDermott, R. S. Prichard et al.
Optimal management of the endometrium in patients with oestrogen receptor‐positive breast cancer taking extended tamoxifen therapy (for 10 years) remains uncertain. A meta‐analysis was performed to determine the cumulative risk ratio (RR) for endometrial malignancy following extended compared with standard tamoxifen treatment. A systematic review was undertaken to identify whether routine endometrial surveillance in patients receiving tamoxifen is associated with earlier detection and reduced incidence of endometrial malignancy.
Two independent searches were undertaken in the Cochrane Library, PubMed and MEDLINE. A meta‐analysis was performed of RCTs reporting on endometrial malignancy risk in extended tamoxifen therapy. A systematic review included prospective studies investigating the benefit of endometrial surveillance during tamoxifen therapy.
Four RCTs reported on endometrial risk in extended tamoxifen therapy. The cumulative risk of endometrial malignancy increased twofold from 1·5 to 3·2 per cent with extended therapy compared with the standard 5 years of tamoxifen (RR 2·29, 95 per cent c.i. 1·60 to 3·28; P < 0·001). Four studies analysed the value of endometrial screening in 5‐year cohorts. Endometrial cancer rates of up to 2 per cent were reported, which is higher than rates in the large extended tamoxifen trials.
Extended adjuvant tamoxifen is associated with an increase in endometrial cancer. No clear benefit has been shown for routine endometrial surveillance in asymptomatic patients on tamoxifen therapy.Full text
You may also be interested in
Authors: Y. Grant, R. Al‐Khudairi, E. St John, M. Barschkett, D. Cunningham, R. Al‐Mufti et al.
Notes: Reoperations expensive
Meta‐analysis of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy‐proven node‐positive breast cancer. BJS 2018; 105: 1541-1552.
Authors: S. R. Tee, L. A. Devane, D. Evoy, J. Rothwell, J. Geraghty, R. S. Prichard et al.
Notes: In selected patients using dual tracer
Feasibility study of combined dynamic imaging and lymphaticovenous anastomosis surgery for breast cancer‐related lymphoedema. BJS 2019; 106: 100-110.
Authors: A. A. Khan, I. Hernan, J. A. Adamthwaite, K. W. D. Ramsey
Notes: Effective in selected patients
Randomized clinical trial
INTEND II randomized clinical trial of intraoperative duct endoscopy in pathological nipple discharge. BJS 2018; 105: 1583-1590.
Authors: G. Gui, A. Agusti, D. Twelves, S. Tang, M. Kabir, C. Montgomery et al.
Notes: Identifies causative lesion
Aesthetic outcome following breast‐conserving surgery assessed by three evaluation modalities in relation to health‐related quality of life. BJS 2019; 106: 90-99.
Authors: C. Dahlbäck, A. Ringberg, J. Manjer
Notes: Better methods needed
Current practice and short‐term outcomes of therapeutic mammaplasty in the international TeaM multicentre prospective cohort study. BJS 2018; 105: 1778-1792.
Authors: R. L. O'Connell, E. Baker, A. Trickey, T. Rattay, L. Whisker, R. D. Macmillan et al.
Notes: Reduces mastectomy rates
Nationwide population‐based study of trends and regional variation in breast‐conserving treatment for breast cancer. BJS 2018; 105: 1768-1777.
Authors: M. C. van Maaren, L. J. A. Strobbe, L. B. Koppert, P. M. P. Poortmans, S. Siesling
Notes: Regional differences remain
Survival and risk of breast cancer recurrence after breast reconstruction with deep inferior epigastric perforator flap. BJS 2018; 105: 1446-1453.
Authors: A. Svee, M. Mani, K. Sandquist, T. Audolfsson, Y. Folkvaljon, A. E. Isern et al.
Best‐practice care pathway for improving management of mastitis and breast abscess. BJS 2018; 105: 1615-1622.
Authors: N. Patani, F. MacAskill, S. Eshelby, A. Omar, A. Kaura, K. Contractor et al.
Notes: Outcomes improve
Meta‐analysis of the diagnostic accuracy of ultrasound‐guided fine‐needle aspiration and core needle biopsy in diagnosing axillary lymph node metastasis. BJS 2018; 105: 1244-1253.
Authors: I. Balasubramanian, C. A. Fleming, M. A. Corrigan, H. P. Redmond, M. J. Kerin, A. J. Lowery et al.
Notes: Core needle biopsy better
Breast‐conserving surgery followed by whole‐breast irradiation offers survival benefits over mastectomy without irradiation. BJS 2018; 105: 1607-1614.
Authors: J. de Boniface, J. Frisell, L. Bergkvist, Y. Andersson
Notes: Radiotherapy to lower axilla key?
Is axillary ultrasound imaging necessary for all patients with breast cancer?. BJS 2018; 105: 930-932.
Authors: M. Ahmed, M. Douek